Evolent Health (EVH)
(Delayed Data from NYSE)
$19.69 USD
+0.07 (0.36%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $19.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
EVH 19.69 +0.07(0.36%)
Will EVH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVH
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
New Strong Buy Stocks for January 5th
Other News for EVH
Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
First Week of August 16th Options Trading For Evolent Health (EVH)
Evolent Health Buy Rating Affirmed by Constantine Davides on Recovery Prospects and Growth Potential
Fly Intel: After-Hours Movers
RA Capital reports 7.1% passive stake in Evolent Health